Vadim Koshkin MD
@koshkin85
Followers
2K
Following
3K
Media
129
Statuses
1K
Associate Professor of Clinical Medicine @UCSF @ucsfcancer focusing on GU Oncology. Alum of @ClevelandClinic @umichmedicine @UChiPritzker Tweet re GU oncology
San Francisco, CA
Joined April 2017
🗣️ Lets talk about management after ADC-CPI progression w/ @koshkin85 from @UCSF #GONORTEGUDebates
0
3
6
0
3
13
Wonderful start to a high-yield conference in beautiful Northern Spain @gonorte_!
0
3
6
@BladderCancerUS @NatureComms Huge thanks to @BladderCancerUS and @BCAN_Research for the YIA+support, amazing med student Kevin Chang & awesome mentors+collaborators @CChuMD @koshkin85 @corynnkasap @felixfengmd @apwiita @DrTFriedlander @SimaPorten @DSolit @DrRosenbergMSK @jklee_lab @UCSFUrology @UCSFCancer
0
3
11
Research funded in part by BCAN with @jonchou05 in @NatureComms : Modulating the PPARÎł pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer. Click here to read the article:
nature.com
Nature Communications - Enfortumab vedotin (EV) is the current standard treatment for advanced bladder cancer, but resistance typically develops within a year, highlighting the need for new...
2
9
22
Intravesical Gemcitabine via TAR200 for BCG - unresponsive NMIBC with CIS +/- papillary tumors is FDA approved. It joins a number of other agents with a spectrum of MOAs. With data generated from single arm trials there is not a clear winner.
6
57
147
Dr. Stefanie Zschäbitz offers a brilliant perspective on how to manage variant #bladdercancer histologies at #IUCS25, citing work from @b_szabados, @koshkin85, @PGrivasMDPhD, @BradMcG04, @AndreaNecchi, @tompowles1 et al!
0
11
16
IMVIGOR011: Atezo vs placebo in ctDNA+ve bladder ca (including -ve becoming +ve) post cystectomy hit OS/PFS. It also tracks outcomes in the ctDNA-ve, supporting a ctDNA adjusted approach. It’s been a long journey for atezo in UC but it has +ve OS at last https://t.co/dPqlvr2rnV
9
114
283
Dr. Vadim Koshkin @koshkin85 on the latest in genitourinary cancers: The AMPLITUDE trial highlights a new role for ADT plus Abiraterone, Prednisone, and Niraparib in HRR-mutant mCSPC. Long-term results reinforce immunotherapy as the standard in RCC, and ctDNA shows prognostic
0
1
5
Kudos to our @fredhutch @uwlabmedpath team @RubenRaychaud @HsiehLab et al. for this important study: T-DXd pan-tumor approval: Test for HER2 using gastric Ca scoring system @CRC_AACR @OncoAlert @montypal @neerajaiims @DrYukselUrun @shilpaonc @Uromigos @HutchPresident @koshkin85
Recently published: Patterns of #HER2 Expression in Metastatic Prostate & Urothelial Cancers: Implications for HER2-Targeted Therapies, by Hyun Jung Lee et al. https://t.co/dfTBJkdePv
@PGrivasMDPhD @hsiehlab @uwlabmedpath @fredhutch #ProstateCancer #UrothelialCancer #OpenAccess
3
12
31
@tompowles1 Great news for our patients - but isn´t it the Keynote-905 (EV-303) instead of KN-901? @OncoAlert @tompowles1 @Uroweb @high5md
merck.com
First and only systemic therapy to improve survival when used before and after surgery for patients with MIBC who are ineligible for cisplatin-based chemotherapy First ever positive Phase 3 study in...
1
1
4
Perioperative EVP shows ⬆️ EFS,OS & pCR vs cystectomy alone in high risk cisplatin ineligible MIBC (KN901). Highly active systemic vs surgery will rescue many patients with aggressive micrometastatic disease. CRs for EVP=30% in M1 but should be ⬆️ in MIBC https://t.co/MEsZvzktTe
6
78
209
R/T, please! Thank you all so much for coming to #BCANTT25. While we're at it, can you please help us spread the word on the BCAN Continuity Grants (for labs who federal funding has been cut or frozen)? Apply by 7/18! https://t.co/m6wILXzjbE
1
5
7
Another great @BladderCancerUS #BCANTT25 meeting in the books! A great session focused on treatments post EV+Pembro led by @siadaneshmand #GopaIyer and great discussion with @PGrivasMDPhD @ERPlimackMD @arkhaki @shilpaonc
An excellent session chaired by @siadaneshmand #GopaIyer on evolving strategies after EV-pembro in bladder cancer @BladderCancerUS #BCANTT25 Excellent multidisciplinary panel sharing insights. Great to have a patient advocate at the table! Lot of unanswered questions re:
1
3
19
CALGB 90601: From Lemons to Lemonade, Possibilities from Negative Cooperative Group Trials. Presentation by @DrRosenbergMSK @MSKCancerCenter. #BCANTT25 written coverage by @chavarriagaj @UofT > https://t.co/kmrvU5Lz9G
@BladderCancerUS
0
5
7
Day ✌️#bcantt25 starting out with @BladderCancerUS Research Innovation Awards . Evaluating JAKi stimulation to boost T cell immunity and exploring therapeutic vulnerabilities for drug development
1
6
16
Big news in bladder cancer. R3 (n=480) of Disitimab Vedotin(HER2ADC) + Tori (PD1) vs chemo, hitting PFS + OS in 1st line irrespective of HER2 . “This reshapes the global treatment landscape of urothelial carcinoma with the Chinese regimen,”said Dr. Jun Guo https://t.co/yz7GePkrOP
4
47
107
Testing and Interpretation of Human Epidermal Growth Factor Receptor 2 Protein Expression and ERBB2 Gene Amplification in Advanced Urothelial Carcinoma. Co-authored by @koshkin85
https://t.co/j2fqSWhc3n
ascopubs.org
PURPOSEThe aim of this study was to assess the prevalence of human epidermal growth factor receptor 2 (HER2) protein expression and ERBB2 gene amplification in a large cohort of tumor samples from...
0
2
11
#ASCO25 abstracts titlkes are out!!!!! https://t.co/ybAeFhH4He Much Looking forward to seeing the exciting new data in GU tumors!!!! See you all in Chicago!!!! @ASCO @ASCOPost @DrChoueiri @tompowles1 @shilpaonc @Heijden @motzermd @GuardConsortium
0
26
89
👉 @koshkin85 and @AmandaNizamMD break down recent research on #pembrolizumab retreatment in patients with advanced or metastatic #urothelial carcinoma who responded to first-course pembrolizumab-based therapy: https://t.co/sUtpOx4ZNQ 🔎 Watch to learn more about the
0
6
13